OncoMatch/Clinical Trials/NCT06927466

A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.

Is NCT06927466 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies B019 for relapsed or refractory b-cell acute lymphoblastic leukemia.

Phase 1RecruitingShanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.NCT06927466Data as of May 2026

Treatment: B019 — The purpose of the study is to evaluate the safety and tolerability of B019 in subjects.

Check if I qualify

Extracted eligibility criteria

Cancer type

Acute Lymphoblastic Leukemia

Biomarker criteria

Required: CD19 expression

Required: CD22 expression

Prior therapy

Cannot have received: CAR-T cell therapy

Has had treatment with any prior CAR-T therapy

Lab requirements

Kidney function

Liver function

Cardiac function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify